文献速递造血干细胞移植与细胞治疗血栓与止血

第三方供者间充质干细胞治疗异基因造血干细胞移植后难治性迟发性出血性膀胱炎的临床研究

[Clinical study of mesenchymal stem cells from third-party donors in the treatment of refractory late onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplanation].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

该回顾性研究纳入20例allo-HSCT后难治性迟发性出血性膀胱炎患者,在常规治疗基础上联合第三方骨髓来源间充质干细胞输注(每次1×10^6/kg、每周1次),总缓解率为90.0%,17例完全缓解、1例部分缓解,未发生MSC输注相关不良反应,尿BKV-DNA及CMV-DNA拷贝数较治疗前显著降低。

要点

  • 第三方骨髓MSC治疗allo-HSCT后难治性LOHC总缓解率90.0%,17例完全缓解、1例部分缓解。
  • MSC输注后第8周尿BKV-DNA及CMV-DNA拷贝数较治疗前显著降低,JCV-DNA无明显改变。
  • 20例患者均未发生MSC输注相关不良反应。

核心结论

  • 第三方骨髓来源MSC对allo-HSCT后难治性LOHC具有显著疗效且安全性良好。

研究设计与样本

  • 回顾性分析2018年7月至2020年6月allo-HSCT后发生难治性LOHC的20例患者,在常规治疗基础上联合第三方骨髓来源MSC治疗。
  • MSC以每次1×10^6/kg、每周1次输注,直至症状改善或连用4次无效停用。
  • 在MSC治疗前及治疗后第8周应用定量PCR法检测尿液标本中BKV、JCV、CMV。

主要发现

  • 20例中男15例、女5例,中位年龄35(15~56)岁;ALL 5例、AML 9例、MDS 5例、BPDCN 1例;HLA全相合移植4例、HLA不全相合移植16例。
  • MSC输注中位次数为3(2~8)次;17例获得完全缓解,1例获得部分缓解,总缓解率为90.0%。
  • 移植后中位随访397.5(39~937)d,13例存活、7例死亡,死亡原因包括急性GVHD 1例、感染5例、TMA 1例。
  • MSC输注后第8周尿BKV-DNA拷贝数较治疗前显著降低(11342.1×10^8拷贝/L vs 5.2×10^8拷贝/L,P=0.016)。
  • MSC输注后第8周尿CMV-DNA拷贝数较治疗前显著降低(3170.0×10^4拷贝/L vs 0.2×10^4拷贝/L,P=0.006);JCV-DNA与治疗前相比无明显改变(P=0.106)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To examine the efficacy and safety of third-party bone marrow-derived mesenchymal stem cells (MSCs) in the treatment of refractory delayed hemorrhagic cystitis (LOHC) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Methods: Twenty patients with refractory LOHC received conventional therapy combined with MSCs obtained from third-party donors' bone marrow (BM) . MSCs were given intravenously at a dose of 1 × 10(6) cells/kg once weekly until either the symptoms improved or no changes in LOHC were seen after continuous infusion four times. BK viruria (BKV) -DNA, JC viruria (JCV) -DNA, and CMV-DNA were detected by real-time quantitative PCR before and 8 weeks after the MSCs infusion. Results: ① Of the 20 patients with refractory LOHC, 15 were males, and 5 were females, and the median age was 35 (15-56) years. There were 5 cases of acute lymphoblastic leukemia (ALL) , 9 cases of acute myeloid leukemia (AML) , 5 cases of myelodysplastic syndrome (MDS) , and 1 case of maternal plasma cell like dendritic cell tumor (BPDCN) . There were 4 cases of HLA identical transplantation and 16 cases of HLA incomplete transplantation. ②The median number of MSC infusions for each patient was 3 (range: 2-8) . Seventeen patients achieved complete response, and one had a partial response after treatment. The overall response rate was 90%. Over a median follow-up period of 397.5 days (range 39-937 days) post-transplantations, 13 patients survived, and 7 died. The causes of death included aGVHD (1 case) , infections (5 cases) , and TMA (1 case) . ③The copy numbers of BKV-DNA and CMV-DNA in urine in the 8th week after MSCs infusion were significantly lower than those observed before treatment (11342.1×10(8) copies/L vs 5.2×10(8) copies/L, P=0.016; 3170.0×10(4) copies/L vs 0.2×10(4) copies/L, P=0.006, respectively) , while JCV-DNA did not significantly differ when compared to before treatment (P=0.106) . ④ No adverse reactions related to MSC infusion occurred in any of the 20 patients. Conclusion: Third-party bone marrow-derived MSC has significant efficacy and good safety in the treatment of refractory LOHC after allogeneic HSCT. 目的: 观察第三方骨髓来源间充质干细胞(MSC)治疗异基因造血干细胞移植(allo-HSCT)后难治性迟发性出血性膀胱炎(LOHC)的疗效和安全性。 方法: 回顾性分析2018年7月至2020年6月allo-HSCT后发生难治性LOHC 20例患者在常规治疗基础上联合第三方骨髓来源MSC治疗。MSC以每次1×10(6)/kg、每周1次输注,直至症状改善或连用4次无效停用。在MSC治疗前及治疗后第8周应用定量PCR法检测患者尿液标本中BK病毒(BKV)、JC病毒(JCV)、巨细胞病毒(CMV)。 结果: ①20例难治性LOHC患者中,男15例、女5例,中位年龄35(15~56)岁;急性淋巴细胞白血病(ALL)5例,急性髓系白血病(AML)9例,骨髓增生异常综合征(MDS)5例,母细胞性浆细胞样树突细胞瘤(BPDCN)1例;HLA全相合移植4例,HLA不全相合移植16例。②MSC输注中位次数为3(2~8)次。17例患者获得完全缓解,1例获得部分缓解,总缓解率为90.0%。移植后中位随访397.5(39~937)d,13例存活、7例死亡,死亡原因包括急性GVHD 1例、感染5例、血栓性微血管病(TMA)1例。③MSC输注后第8周尿BKV-DNA及CMV-DNA拷贝数较治疗前显著降低(11342.1×10(8)拷贝/L对5.2×10(8)拷贝/L,P=0.016;3170.0×10(4)拷贝/L对0.2×10(4)拷贝/L,P=0.006),而JCV-DNA与治疗前相比无明显改变(P=0.106)。④未发生MSC输注相关不良反应。 结论: 第三方骨髓来源MSC对allo-HSCT后难治性LOHC具有显著疗效且安全性良好。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhao K, Huang F, Chen XY, et al. [Clinical study of mesenchymal stem cells from third-party donors in the treatment of refractory late onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplanation]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35968592. doi:10.3760/cma.j.issn.0253-2727.2022.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。